Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.

Invested in 2010

Acquired by Gilead in 2015

Based in Foster City, California, USA 

Lundbeckfonden Emerge


AFYX Therapeutics Presents Results from Rivelin Clinical Proof of Concept Study in Patients with Vulvar Lichen Sclerosus at the 2019 European Academy of Dermatology and Venereology Congress
10. October 2019
23 Danish biotech companies meet investors in New York
3. April 2019
SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials
11. March 2019